Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842287 | 0.87 | HDAC1 (0.51) | HDAC1HDAC8 | |
| SCHEMBL15341326 | 0.79 | KMT2A (0.47) | KMT2AKDM4E | |
| SCHEMBL868061 | 0.78 | HDAC1 (0.51) | HDAC1HDAC8 | |
| SCHEMBL10173246 | 0.76 | HDAC1 (0.48) | HDAC1HDAC8 | |
| SCHEMBL3399885 | 0.76 | HDAC1 (0.78) | HDAC1HDAC8 | |
| SCHEMBL3399883 | 0.76 | HDAC1 (0.78) | HDAC1HDAC8 | |
| SCHEMBL3606510 | 0.76 | POLB (0.48) | HDAC1HDAC8KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL3372032 | 0.74 | HDAC1 (0.53) | HDAC1HDAC8KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL3372037 | 0.74 | HDAC1 (0.53) | HDAC1HDAC8KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL3367324 | 0.72 | HDAC1 (0.78) | HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10736881-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190282547-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2019-09-19 | — | — | US | disclosed |
| US-10201527-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170360757-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2017-12-21 | — | — | US | disclosed |
| US-9717713-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160279102-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2016-09-29 | — | — | US | disclosed |
| US-9402829-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150157608-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2015-06-11 | — | — | US | disclosed |
| US-9024029-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140005194-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | MEI PHARMA, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8551988-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20100256138-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2010-10-07 | — | — | US | disclosed |
| US-7781595-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2010-08-24 | — | — | US | disclosed |
| EP-1673349-B1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S BIO PTE LTD (SG) | 2010-06-30 | — | — | EP | disclosed |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201527-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885KMT2A 96/4885 |
| US-20190282547-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885KMT2A 96/4885 |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC4 | HDAC1 2/4885HDAC8 4/4885KMT2A 84/4885 |
| US-10736881-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885KMT2A 96/4885 |
| US-20140005194-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885KMT2A 96/4885 |
| US-20100256138-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885KMT2A 96/4885 |
| US-20160279102-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885KMT2A 96/4885 |
| US-20170360757-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885KMT2A 96/4885 |
| US-20150157608-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | HDAC1 2/4885HDAC8 3/4885KMT2A 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.